Drug Details

General Information of the Drug (ID: DR8712)
Name
C1632
Disease Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Metformin      Galega officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [1]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression HMGA2  Molecule Info 
Pathway MAP
Down-regulation Expression Lin-28A  Molecule Info 
Pathway MAP
                    In-vitro Model SCC-9 CVCL_1685 Tongue squamous cell carcinoma Homo sapiens
CAL-27 CVCL_1107 Tongue squamous cell carcinoma Homo sapiens
                    In-vivo Model Each nude mouse was subcutaneously injected in the flank back skin with 200 uL of serum-free DMEM containing 8 * 106 CAL27 cells.
                    Experimental
                    Result(s)		 C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo.
Target and Pathway
Target(s) Thymidylate kinase (DTYMK)  Molecule Info  [2]
References
Reference 1 In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma. Eur J Pharmacol. 2021 Jan 15;891:173757.
Reference 2 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link